Home » Abbott’s Neuropathic Pain Blocker Cleared for Marketing
Abbott’s Neuropathic Pain Blocker Cleared for Marketing
The FDA and EU have both cleared Abbott’s DRG Invisible Trial system for marketing, a device designed to help people suffering from neuropathic pain.
The device targets the dorsal root ganglion (DRG), a nerve structure near the spinal cord that transmits chronic pain to the nervous system.
By transmitting electrical pulses through a thin wire placed in the spinal column near the DRG, the system blocks pain signals from reaching the nervous system.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May